Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.
UNITED STATES : Tetraphase awarded $36 million contract for the Development of a Novel Tetraphase Antibiotic
Publish Date : 21-Oct-2011
Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company has been awarded a contract worth up to $36 million for the development of TP-271 by National Institutes of Health\'s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). Tetraphase will be working on this contract as a sub-contractor to Buffalo, NY-based CUBRC, Inc.
Guy Macdonald, president and chief executive officer of Tetraphase said \"We are pleased that NIAID has granted an award to support the development of TP-271, which will be the fourth compound to enter development from our novel chemistry platform. He further stated that We are honored to be at the forefront of the development of potential solutions to these growing threats.\"
The NIAID award covers development, manufacturing, and clinical activities to position TP-271 for further development against certain biothreat agents, including Francisella tularensis, which causes tularemia, Yersinia pestis, which causes bubonic plague, and Bacillus anthracis, which causes anthrax disease, and bacterial pathogens associated with community-acquired bacterial pneumonia (CABP), a significant public health threat and commercial market opportunity.
The contract includes a 25-month base period with committed funding of nearly $6 million and subsequent option periods that, if completed, would bring the total value of the award to almost $36 million.
